Join to View Full Profile
605 Glenwood DrSuite 200Chattanooga, TN 37404
Phone+1 423-698-1844
Fax+1 423-624-2226
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 1 invite waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Brooke Daniel, MD is an oncologist in Chattanooga, Tennessee. She is currently licensed to practice medicine in Tennessee, Florida, and Georgia.
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 2002 - 2005
Virginia Commonwealth University Health SystemResidency, Internal Medicine, 1998 - 2001
University of Tennessee Health Science Center College of MedicineClass of 1998
Certifications & Licensure
FL State Medical License 2020 - Present
GA State Medical License 2005 - 2027
TN State Medical License 2005 - 2027
VA State Medical License 1998 - 2006- VA State Medical License 1998 - 2006
NC State Medical License 2002 - 2005
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ARIA oncology information system (for Medical Oncology), Varian Medical Systems, 2012, 2014-2017
- CMS Meaningful Use Stage 2 Certification ARIA Oncology Information System (for Medical Oncology), Varian Medical Systems, 2012, 2014-2017
- CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc, 2012, 2014-2017
Publications & Presentations
PubMed
- Advancing the Care of Women With HER2-Positive Metastatic Breast Cancer.Marcie Beasley, Brooke Daniel
Journal of the Advanced Practitioner in Oncology. 2023-04-01 - 5 citationsPhase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapyDenise A. Yardley, N. W. Peacock, Brooke R. Daniel, Betrand Anz, David C. Molthrop
Breast Cancer Research and Treatment. 2020-02-14 - 21 citationsTITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancerDenise A. Yardley, Edward Arrowsmith, Brooke R. Daniel, Janice F. Eakle, Adam Brufsky
Breast Cancer Research and Treatment. 2017-05-15
Press Mentions
Champions of Health Care 2024: CHI Memorial HospitalSeptember 1st, 2024- OneOncology Names Dr. Davey Daniel as Chief Medical OfficerFebruary 7th, 2022
